![Mark McCamish](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark McCamish
Directeur Général chez
IconOVir Bio, Inc.
Profil
Mark A. McCamish is currently President & Chief Executive Officer at IconOVir Bio, Inc. Former positions include President, Chief Executive Officer & Director at Forty Seven LLC from 2017 to 2020; Director at Abbott Laboratories in 1997; Independent Director at Avadel Pharmaceuticals Plc from 2019 to 2026; Independent Director at Vincerx Pharma, Inc. from 2020 to 2021; Independent Director at Rafael Holdings, Inc. from 2021 to 2024; Chief Medical Officer & VP-Clinical Development at Perlegen Sciences, Inc. from 2003 to 2007; Global Head-Biopharmaceutical Development at Sandoz, Inc. from 2009 to 2017; Chief Medical Officer & Senior Vice President at Abbott Biotherapeutics Corp.
from 2008 to 2009; Professor at The Ohio State University; Professor at the University of California, Davis; and Chief Medical Officer & Senior Vice President at PDL BioPharma, Inc. from 2007 to 2008.
Education includes a doctorate from The Pennsylvania State University conferred in 1980; undergraduate and graduate degrees from the University of California, Santa Barbara in 1976 and 1977 respectively; and a doctorate from David Geffen School of Medicine.
Postes actifs de Mark McCamish
| Sociétés | Poste | Début |
|---|---|---|
IconOVir Bio, Inc.
 IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Directeur Général | 01/11/2020 |
Anciens postes connus de Mark McCamish
| Sociétés | Poste | Fin |
|---|---|---|
| AVADEL PHARMACEUTICALS PLC | Directeur/Membre du Conseil | 12/02/2026 |
| RAFAEL HOLDINGS, INC. | Directeur/Membre du Conseil | 05/08/2024 |
| VINCERX PHARMA, INC. | Directeur/Membre du Conseil | 13/05/2021 |
| FORTY SEVEN, INC. | Directeur Général | 07/04/2020 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Corporate Officer/Principal | 01/04/2017 |
Formation de Mark McCamish
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
74
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Abbott Laboratories
 Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Discovers and develops drugs | Retail Trade |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for the treatment of oncology and immunologic diseases | Health Technology |
The Ohio State University
 The Ohio State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
 The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that manufactures and wholesales prescription medicine products | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
David Geffen School of Medicine
 David Geffen School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avadel Pharmaceuticals Plc
 Avadel Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Rafael Holdings, Inc.
 Rafael Holdings, Inc. Real Estate DevelopmentFinance Operates as holding company with interest in real estate and pharmaceutical sector | Finance |
IconOVir Bio, Inc.
IconOVir Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops oncolytic virus therapy to improve the treatment of patients with cancer | Health Technology |
Vincerx Pharma, Inc.
 Vincerx Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies to address cancer | Health Technology |
